A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy

Clinical Cancer Research

Volumn 10, Issue 10, 2004, Pages 3265-3272

  Sandler, Alan ^a,c   Gordon, Michael ^a,d   De Alwis, Dinesh P ^b   Pouliquen, Isabelle ^b   Green, Lisa ^b   Marder, Phil ^b   Chaudhary, Ajai ^b   Fife, Karen ^a   Battiato, Linda ^a   Sweeney, Christopher ^a   Jordan, Christopher ^b   Burgess, Michael ^b   Slapak, Christopher A ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; ZOSUQUIDAR;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; COHORT STUDIES; DIBENZOCYCLOHEPTENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; QUINOLINES; TIME FACTORS;

EID: 2542479863     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0644     Document Type: Article

References (19)

1. Goldstein LJ, Gaslki H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst (Bethesda) 1989;81:116-24.
2. Ford JM, Yang JM, Hait WN. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res 1996;87:3-38.
3. Sikic BI, Fisher GA, Lum BL, et al. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40:S13-9.
4. Sato W, Fukazawa N, Suzuki T, et al. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 1991;51:2420-4.
5. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-9.
6. Green LJ, Marder P, Slapak CA. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 2001;61:1393-9.
7. Reddy VR, Buben JA, Truex LL, et al. The toxicity and pharmacokinetic interaction of LY335979, an inhibitor of P-glycoprotein, with doxorubicin in beagle dogs [abstract]. Proc Am Assoc Cancer Res 1998;39:512a.
8. Rubin EH, De Alwis DP, Pouliquen I, et al. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2002;8:3710-7.
9. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment, Cancer (Phila) 1981;47:207-14.
10. Keene ON. The log transformation is special. Stat Med 1995;14:811-9.
11. Klimecki WT, Futscher BW, Grogan TM, et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-8.
12. + cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 1999;93:306-14.
13. Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997;3:2005-15.
14. Rowinsky EK, Smith L, Wang YM, et al. Phase 1 and pharmacokinetic study of paclitaxel in combination with Biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 1998;16:2964-76.
15. Dantzig AH, De Alwis DP, Burgess, M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 2003;55:133-50.
16. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 1996;97:2517-24.
17. Spahn-Langguth H, Baktir G, Radschuweit A, et al. P-Glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as a model compound. Int J Clin Pharmacol Ther 1998;36:16-24.
18. Van Zuylen L, Sparreboom A, van der Gaast A, et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 2000;6:1365-71.
19. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.